SCOUT· 33%39m·2026-11-12·TechnologyPowering AI-Driven Drug Discovery with President of Isomorphic Labs Max Jaderberg
Drug discovery and development has long relied on expensive, time-consuming empirical trial and error. By shifting the discovery process onto computers, Isomorphic Labs wants to fundamentally change medicine from a process of discovery to one of precision engineering. Elad Gil sits down with Isomorphic’s president Max…
Scout bees are checking it out — divided opinions, the swarm hasn't committed.
- Platform
- 33%
- Community
- no read yet
- Value
- no read yet
Buzzmeter says it's buzzing across platforms — the Hive Vote says whether the people who actually listened liked it.
Rate this episode
Add your vote to the Hive — listeners rate every episode after they finish.
- No reviews yet — be the first.
What people are saying
“I’ve worked in Biopharma for almost a decade now. No one is worried about the CS tech guys trying their hand at drug development. Biology is a thresher and all of these efforts are chaff.”
“Moving drug discovery from trial and error to precision engineering is a big shift for a field built on experiments. I'm curious how Max thinks about validation: if predictive models reach experimental accuracy, which part of the lab work w…”
More from No Priors: Artificial Intelligence | Technology | Startups
See all episodes →
63%From Restoring Sight to Reimagining the Brain, with Max Hodak
60%Redefining Chip Architecture with Arm CEO Rene Haas
58%Rethinking Legacy Data Infrastructure with Eon Co-Founders Ofir Ehrlich and Gonen Stein
One great episode in your inbox, daily — free.
One email a day, unsubscribe anytime. No spam, ever.